Susan T Vadaparampil1, Juliette Christie2, Kristine A Donovan3, Jongphil Kim3, Bianca Augusto3, Monica L Kasting3, Cheryl L Holt2, Kimlin Ashing4, Chanita Hughes Halbert5, Tuya Pal3. 1. Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA. susan.vadaparampil@moffitt.org. 2. University of Maryland, 4200 Valley Drive, Room 1242W, College Park, MD, 20742, USA. 3. Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA. 4. City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. 5. Medical University of South Carolina, 68 President Street, Charleston, SC, 29425, USA.
Abstract
PURPOSE: Black women are more likely to develop early-onset (≤50 years) breast cancer (BC) and have the lowest five-year, cause-specific survival rate of any United States (U.S.) racial or ethnic group. These disparities can be attributed partially to the higher rate of triple-negative BC (TNBC) in Blacks. Yet, little is known about health-related quality of life (HRQOL) among Black women with TNBC. METHODS: Black women with invasive BC ≤ 50 years were recruited via the Florida Cancer Data System as part of a population-based case-only study of etiology and outcomes of early-onset invasive BC. Of 460 consented participants, a subset of 355 self-reported sociodemographic, clinical, and psychosocial variables. Descriptive analyses included participants with known TNBC (n = 85) or non-TNBC (n = 245) disease. Univariable and multivariable analyses were conducted to examine differences in factors associated with HRQOL. RESULTS: In unadjusted analyses, TNBC participants had significantly lower FACT-B total scores (90.1 ± 27.9) compared to non-TNBC (98.5 ± 27.6) participants (p < 0.05). For the TNBC group, multivariable analyses indicated five individual-level, and three systemic-level factors explain 80% of the response variation in HRQOL. For the non-TNBC group, seven individual-level factors and three systemic-level factors account for 76% of the variation in HRQOL scores. CONCLUSIONS: Compared to Black women with non-TNBC, TNBC women have worse HRQOL. There are key individual and systemic-level factors that are unique to both groups. Findings can inform future HRQOL interventions to support young Black BC survivors.
PURPOSE: Black women are more likely to develop early-onset (≤50 years) breast cancer (BC) and have the lowest five-year, cause-specific survival rate of any United States (U.S.) racial or ethnic group. These disparities can be attributed partially to the higher rate of triple-negative BC (TNBC) in Blacks. Yet, little is known about health-related quality of life (HRQOL) among Black women with TNBC. METHODS: Black women with invasive BC ≤ 50 years were recruited via the Florida Cancer Data System as part of a population-based case-only study of etiology and outcomes of early-onset invasive BC. Of 460 consented participants, a subset of 355 self-reported sociodemographic, clinical, and psychosocial variables. Descriptive analyses included participants with known TNBC (n = 85) or non-TNBC (n = 245) disease. Univariable and multivariable analyses were conducted to examine differences in factors associated with HRQOL. RESULTS: In unadjusted analyses, TNBC participants had significantly lower FACT-B total scores (90.1 ± 27.9) compared to non-TNBC (98.5 ± 27.6) participants (p < 0.05). For the TNBC group, multivariable analyses indicated five individual-level, and three systemic-level factors explain 80% of the response variation in HRQOL. For the non-TNBC group, seven individual-level factors and three systemic-level factors account for 76% of the variation in HRQOL scores. CONCLUSIONS: Compared to Black women with non-TNBC, TNBC women have worse HRQOL. There are key individual and systemic-level factors that are unique to both groups. Findings can inform future HRQOL interventions to support young Black BC survivors.
Entities:
Keywords:
Black women; Breast cancer; Quality of life; Triple-negative breast cancer
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Eric C Dietze; Christopher Sistrunk; Gustavo Miranda-Carboni; Ruth O'Regan; Victoria L Seewaldt Journal: Nat Rev Cancer Date: 2015-02-12 Impact factor: 60.716
Authors: Phuong Khanh Morrow; Anita C Broxson; Mark F Munsell; Karen Basen-Enquist; Carol K Rosenblum; Leslie R Schover; Lynne H Nguyen; Limin Hsu; Lilibeth Castillo; Karin M Hahn; Jennifer K Litton; Danielle N Kwiatkowski; Gabriel N Hortobagyi Journal: Clin Breast Cancer Date: 2013-10-25 Impact factor: 3.225
Authors: Cleo A Samuel; Laura C Pinheiro; Katherine E Reeder-Hayes; Jennifer S Walker; Giselle Corbie-Smith; Shekinah A Fashaw; Cheryl Woods-Giscombe; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2016-09-06 Impact factor: 4.872
Authors: Nora L Nock; Cynthia Owusu; Susan Flocke; Susan A Krejci; Emily L Kullman; Kris Austin; Beth Bennett; Stephen Cerne; Carl Harmon; Halle Moore; Mary Vargo; Paul Hergenroeder; Hermione Malone; Michael Rocco; Russell Tracy; Hillard M Lazarus; John P Kirwan; Ellen Heyman; Nathan A Berger Journal: Int J Sports Exerc Med Date: 2015-09-05
Authors: Valerie Jenkins; Ryan Thwaites; Mara Cercignani; Sandra Sacre; Neil Harrison; Hefina Whiteley-Jones; Lisa Mullen; Giselle Chamberlain; Kevin Davies; Charles Zammit; Lucy Matthews; Helena Harder Journal: Springerplus Date: 2016-03-31
Authors: Benjamin Ansa; Wonsuk Yoo; Mary Whitehead; Steven Coughlin; Selina Smith Journal: Int J Environ Res Public Health Date: 2015-12-23 Impact factor: 3.390
Authors: Cathleen Y Xing; Michelle Doose; Bo Qin; Yong Lin; Tiffany L Carson; Jesse J Plascak; Kitaw Demissie; Chi-Chen Hong; Elisa V Bandera; Adana A M Llanos Journal: Breast Cancer Res Treat Date: 2020-09-10 Impact factor: 4.872
Authors: Min Huang; Amin Haiderali; Grace E Fox; Andrew Frederickson; Javier Cortes; Peter A Fasching; Joyce O'Shaughnessy Journal: Pharmacoeconomics Date: 2022-02-03 Impact factor: 4.558